CSI Market
Sign In | Register

Acadia Pharmaceuticals Inc (ACAD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACAD Annual Cash Flow →
This cash flow overview for Acadia Pharmaceuticals Inc spans from Jun 30 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income35.14
Depreciation & amortization0.71
Amortization of Other Assets5.45
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.98
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation31.64
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Increase Decrease In Operating Lease Assets2.16
Increase Decrease In Operating Lease Liabilities-2.18
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable29.19
Accounts Payable22.59
Increase (Decrease) in Accrued Liabilities46.09
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense9.84
Other Working Capital-4.18
Other Noncash Income (Expense)0.00
Other net0.50
Payments for (Proceeds from) Other Operating Activities-38.22
Discontinued operations0.00
Net Cash flow from Operating Activities134.76
Investing Activities
Capital Expenditures-10.30
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities176.50
Payments to Acquire Available-for-sale Securities, Debt-108.45
Real Estate Investments0.00
Regulatory Milestone Payment-
Proceeds From Sales Of Strategic Investment-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities57.75
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock14.73
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations185.54
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities14.73
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow124.46
Total Cash Flow207.29
4 historic quarters locked

Sign in to unlock the full Acadia Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Acadia Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-333243

Figures are derived from filed reports and may be restated. Historical data is subject to revision.